

## JOINT CLARIFICATION REGARDING AGREEMENT BETWEEN CARDIO3 BIOSCIENCES AND MAYO CLINIC

**Mont-Saint-Guibert, Belgium** - Mayo Clinic and Cardio3 Biosciences recently entered into a non-exclusive preferred access agreement. This agreement builds on a long established and productive relationship of licensing and research in the area of cardiac regeneration. The mutual hope for this work is that together Mayo Clinic and Cardio3 BioSciences can accelerate Mayo Clinic discoveries toward clinical application.

Under the collaboration agreement, the parties have agreed to regular periodic meetings to review Mayo Clinic's regenerative medicine portfolio to identify areas and projects of mutual interest. The results of these conversations could potentially lead to cooperative research projects, license agreements or introductions to third parties to further the technology. The agreement does not prevent Mayo Clinic from working with other potential commercial partners in the same manner.

Mayo Clinic and Cardio3 BioSciences look forward to this ongoing collaboration and both believe that together they can continue to move promising technologies towards patients.

**\*\* END \*\***

For more information, please contact:

**Cardio3 BioSciences**

Christian Homsey, CEO

Julie Grade, Corporate Communications Manager

[www.c3bs.com](http://www.c3bs.com)

Tel. : +32 10 39 41 00

[jgrade@c3bs.com](mailto:jgrade@c3bs.com)

**For Europe: Citigate Dewe Rogerson**

Chris Gardner

Tel : +44 (0) 207 638 9571

[Chris.Gardner@citigatedr.co.uk](mailto:Chris.Gardner@citigatedr.co.uk)

**For the U.S: Rx Communications Group**

Eric Goldman

Tel: +1 917 322 2563

[egoldman@RxIR.com](mailto:egoldman@RxIR.com)

To subscribe to Cardio3 BioSciences' newsletter, visit [www.c3bs.com](http://www.c3bs.com).

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

**About Cardio3 BioSciences**

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure<sup>®</sup> is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure<sup>®</sup> consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath<sup>®ezr</sup>, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.



PRESS RELEASE

15 OCTOBER 2014

3:00 PM CET

### **About Mayo Clinic**

Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit [www.150years.mayoclinic.org](http://www.150years.mayoclinic.org) ; [www.mayoclinic.org](http://www.mayoclinic.org) ; and [www.newsnetwork.mayoclinic.org](http://www.newsnetwork.mayoclinic.org) .

*C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.*